Genmab: 5.5% Stake Reported by Orbis & Allan Gray
Genmab A/S ownership disclosure: two institutional investors filed an amended Schedule 13G/A reporting beneficial ownership positions in Genmab common stock.
Rhea-AI Filing Summary
Genmab A/S ownership disclosure: two institutional investors filed an amended Schedule 13G/A reporting beneficial ownership positions in Genmab common stock. The filing shows 3,557,484 shares beneficially owned representing 5.5% of the class and identifies Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd as the reporting persons.
The filing breaks the holdings down by voting and dispositive power: Orbis holds 3,549,674 shares with sole voting and dispositive power, and Allan Gray Australia holds 7,810 shares with sole voting and dispositive power. The filing states the reporting persons are non-U.S. institutions functionally equivalent to an investment adviser and disclaims group beneficial ownership.
Positive
- None.
Negative
- None.
Insights
Large passive stake reported by two non-U.S. institutions (5.5% combined).
The filing documents a combined 5.5% beneficial stake in Genmab common stock held by Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd, with detailed breakdowns of sole voting and dispositive power. This indicates substantial institutional interest.
Key dependencies include any future amendments or sales filed by these holders; subsequent filings would show changes in position. The filing does not state trading intent or planned disposals.
Filing conforms to Schedule 13G/A disclosure for non-U.S. institutional investors.
The amendment classifies the reporting persons as Non-U.S. Institutions equivalent to investment advisers and includes a certification regarding a comparable foreign regulatory scheme. It disclaims group membership and provides signatures with attorney-in-fact attestations.
Material qualifiers include the functional equivalence statement and an offer to furnish Schedule 13D-level information on request; these preserve regulatory compliance without asserting additional rights or arrangements.
Key Figures
Key Terms
beneficially owned regulatory
sole dispositive power regulatory
Schedule 13G/A regulatory
Non-U.S. Institution (FI) regulatory
FAQ
What stake in GENMAB does Orbis Investment Management report?
What total percentage of Genmab does the Schedule 13G/A show?
How much does Allan Gray Australia hold in GENMAB according to this filing?
Do the reporting persons claim to be a group under Section 13(d)?
What regulatory classification do the filers assert?
AI-generated analysis. How Rhea-AI works. Not financial advice.